<!DOCTYPE html><html lang="en" class="dark"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/_next/static/media/e4af272ccee01ff0-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="stylesheet" href="/_next/static/css/8d323862949ffad9.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/webpack-d2cf98d9cef4ff37.js"/><script src="/_next/static/chunks/ceb5afef-fd730bca4742d10d.js" async=""></script><script src="/_next/static/chunks/156-5c70558397be49ef.js" async=""></script><script src="/_next/static/chunks/main-app-f896963268641fe0.js" async=""></script><script src="/_next/static/chunks/863-822c2cde35e02348.js" async=""></script><script src="/_next/static/chunks/app/layout-fb78cfc571d4c3d6.js" async=""></script><title>Unloxcyt Market Survey - Interactive Presentation</title><meta name="description" content="Comprehensive market analysis of Cosibelimab-ipdl for advanced cSCC"/><meta name="next-size-adjust"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule=""></script></head><body class="__className_f367f3 h-1080px w-1920px"><!--$!--><template data-dgst="BAILOUT_TO_CLIENT_SIDE_RENDERING"></template><!--/$--><div class="relative overflow-hidden w-[1920px] h-[1080px] bg-gradient-to-br from-slate-900 to-slate-700 text-white"><div class="flex flex-col w-full h-full"><div class="flex-none bg-slate-800/90 p-6 flex items-center gap-4"><svg xmlns="http://www.w3.org/2000/svg" width="48" height="48" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-target text-purple-400"><circle cx="12" cy="12" r="10"></circle><circle cx="12" cy="12" r="6"></circle><circle cx="12" cy="12" r="2"></circle></svg><h1 class="text-6xl font-bold text-white">SWOT Analysis</h1></div><div class="flex-1 min-h-0 grid grid-cols-2 grid-rows-2 gap-6 p-8"><div class="bg-slate-800/90 border-t-4 border-green-400 rounded-lg p-6"><div class="flex items-center gap-4 mb-6"><svg xmlns="http://www.w3.org/2000/svg" width="36" height="36" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-green-400"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><h3 class="text-4xl font-bold text-green-400">Strengths</h3></div><div class="space-y-3"><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-green-400 mt-1"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><p class="text-2xl">First and only FDA-approved PD-L1 inhibitor for advanced cSCC</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-green-400 mt-1"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><p class="text-2xl">Differentiated ADCC mechanism beyond checkpoint blockade</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-green-400 mt-1"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><p class="text-2xl">Strong clinical data: 47-48% ORR with durable responses</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-green-400 mt-1"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><p class="text-2xl">Sun Pharma&#x27;s global commercialization infrastructure</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-green-400 mt-1"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><p class="text-2xl">Favorable safety profile for immunocompromised patients</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-green-400 mt-1"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><p class="text-2xl">$1B+ addressable U.S. market opportunity</p></div></div></div><div class="bg-slate-800/90 border-t-4 border-orange-400 rounded-lg p-6"><div class="flex items-center gap-4 mb-6"><svg xmlns="http://www.w3.org/2000/svg" width="36" height="36" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-alert text-orange-400"><circle cx="12" cy="12" r="10"></circle><line x1="12" x2="12" y1="8" y2="12"></line><line x1="12" x2="12.01" y1="16" y2="16"></line></svg><h3 class="text-4xl font-bold text-orange-400">Weaknesses</h3></div><div class="space-y-3"><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-alert text-orange-400 mt-1"><circle cx="12" cy="12" r="10"></circle><line x1="12" x2="12" y1="8" y2="12"></line><line x1="12" x2="12.01" y1="16" y2="16"></line></svg><p class="text-2xl">Late market entry vs. established PD-1 competitors (Keytruda, Libtayo)</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-alert text-orange-400 mt-1"><circle cx="12" cy="12" r="10"></circle><line x1="12" x2="12" y1="8" y2="12"></line><line x1="12" x2="12.01" y1="16" y2="16"></line></svg><p class="text-2xl">Limited head-to-head clinical trial data</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-alert text-orange-400 mt-1"><circle cx="12" cy="12" r="10"></circle><line x1="12" x2="12" y1="8" y2="12"></line><line x1="12" x2="12.01" y1="16" y2="16"></line></svg><p class="text-2xl">Historical manufacturing delays (complete response letter)</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-alert text-orange-400 mt-1"><circle cx="12" cy="12" r="10"></circle><line x1="12" x2="12" y1="8" y2="12"></line><line x1="12" x2="12.01" y1="16" y2="16"></line></svg><p class="text-2xl">Pricing parity strategy limits premium positioning</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-alert text-orange-400 mt-1"><circle cx="12" cy="12" r="10"></circle><line x1="12" x2="12" y1="8" y2="12"></line><line x1="12" x2="12.01" y1="16" y2="16"></line></svg><p class="text-2xl">Pre-acquisition company had minimal revenue history</p></div></div></div><div class="bg-slate-800/90 border-t-4 border-blue-400 rounded-lg p-6"><div class="flex items-center gap-4 mb-6"><svg xmlns="http://www.w3.org/2000/svg" width="36" height="36" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-trending-up text-blue-400"><polyline points="22 7 13.5 15.5 8.5 10.5 2 17"></polyline><polyline points="16 7 22 7 22 13"></polyline></svg><h3 class="text-4xl font-bold text-blue-400">Opportunities</h3></div><div class="space-y-3"><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-trending-up text-blue-400 mt-1"><polyline points="22 7 13.5 15.5 8.5 10.5 2 17"></polyline><polyline points="16 7 22 7 22 13"></polyline></svg><p class="text-2xl">Indication expansion: Earlier-stage cSCC, other skin cancers (3-5x population)</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-trending-up text-blue-400 mt-1"><polyline points="22 7 13.5 15.5 8.5 10.5 2 17"></polyline><polyline points="16 7 22 7 22 13"></polyline></svg><p class="text-2xl">European market entry: EMA/UK approvals ($250-400M potential)</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-trending-up text-blue-400 mt-1"><polyline points="22 7 13.5 15.5 8.5 10.5 2 17"></polyline><polyline points="16 7 22 7 22 13"></polyline></svg><p class="text-2xl">Asia-Pacific expansion via Sun Pharma network</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-trending-up text-blue-400 mt-1"><polyline points="22 7 13.5 15.5 8.5 10.5 2 17"></polyline><polyline points="16 7 22 7 22 13"></polyline></svg><p class="text-2xl">Combination therapy protocols with radiation/other agents</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-trending-up text-blue-400 mt-1"><polyline points="22 7 13.5 15.5 8.5 10.5 2 17"></polyline><polyline points="16 7 22 7 22 13"></polyline></svg><p class="text-2xl">Biomarker-driven patient selection improving outcomes</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-trending-up text-blue-400 mt-1"><polyline points="22 7 13.5 15.5 8.5 10.5 2 17"></polyline><polyline points="16 7 22 7 22 13"></polyline></svg><p class="text-2xl">Real-world evidence generation for competitive advantage</p></div></div></div><div class="bg-slate-800/90 border-t-4 border-red-400 rounded-lg p-6"><div class="flex items-center gap-4 mb-6"><svg xmlns="http://www.w3.org/2000/svg" width="36" height="36" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-triangle-alert text-red-400"><path d="m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3"></path><path d="M12 9v4"></path><path d="M12 17h.01"></path></svg><h3 class="text-4xl font-bold text-red-400">Threats</h3></div><div class="space-y-3"><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-triangle-alert text-red-400 mt-1"><path d="m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3"></path><path d="M12 9v4"></path><path d="M12 17h.01"></path></svg><p class="text-2xl">Intense competition from Keytruda/Libtayo with established market share</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-triangle-alert text-red-400 mt-1"><path d="m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3"></path><path d="M12 9v4"></path><path d="M12 17h.01"></path></svg><p class="text-2xl">Potential biosimilar competition post-patent expiration (2036+)</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-triangle-alert text-red-400 mt-1"><path d="m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3"></path><path d="M12 9v4"></path><path d="M12 17h.01"></path></svg><p class="text-2xl">Reimbursement challenges and payer utilization management</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-triangle-alert text-red-400 mt-1"><path d="m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3"></path><path d="M12 9v4"></path><path d="M12 17h.01"></path></svg><p class="text-2xl">Emerging next-generation checkpoint inhibitors</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-triangle-alert text-red-400 mt-1"><path d="m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3"></path><path d="M12 9v4"></path><path d="M12 17h.01"></path></svg><p class="text-2xl">Healthcare reform and drug pricing legislation risks</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-triangle-alert text-red-400 mt-1"><path d="m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3"></path><path d="M12 9v4"></path><path d="M12 17h.01"></path></svg><p class="text-2xl">Manufacturing and supply chain vulnerabilities</p></div></div></div></div><div class="flex-none p-4 text-right"><p class="text-xl text-gray-400">7</p></div></div></div><script src="/_next/static/chunks/webpack-d2cf98d9cef4ff37.js" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0]);self.__next_f.push([2,null])</script><script>self.__next_f.push([1,"1:HL[\"/_next/static/media/e4af272ccee01ff0-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n2:HL[\"/_next/static/css/8d323862949ffad9.css\",\"style\"]\n"])</script><script>self.__next_f.push([1,"3:I[5616,[],\"\"]\n5:I[6146,[],\"\"]\n6:I[4411,[],\"\"]\n7:\"$Sreact.suspense\"\n8:I[7256,[\"863\",\"static/chunks/863-822c2cde35e02348.js\",\"185\",\"static/chunks/app/layout-fb78cfc571d4c3d6.js\"],\"KeyboardNavigation\"]\n9:I[5407,[\"863\",\"static/chunks/863-822c2cde35e02348.js\",\"185\",\"static/chunks/app/layout-fb78cfc571d4c3d6.js\"],\"SlideNavigation\"]\nb:I[7141,[],\"\"]\nc:[]\n"])</script><script>self.__next_f.push([1,"0:[\"$\",\"$L3\",null,{\"buildId\":\"DkpgZd6XOJjDaY981EGFp\",\"assetPrefix\":\"\",\"urlParts\":[\"\",\"pages\",\"7\"],\"initialTree\":[\"\",{\"children\":[\"pages\",{\"children\":[\"7\",{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],\"initialSeedData\":[\"\",{\"children\":[\"pages\",{\"children\":[\"7\",{\"children\":[\"__PAGE__\",{},[[\"$L4\",[\"$\",\"div\",null,{\"className\":\"relative overflow-hidden w-[1920px] h-[1080px] bg-gradient-to-br from-slate-900 to-slate-700 text-white\",\"children\":[\"$\",\"div\",null,{\"className\":\"flex flex-col w-full h-full\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex-none bg-slate-800/90 p-6 flex items-center gap-4\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":48,\"height\":48,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-target text-purple-400\",\"children\":[[\"$\",\"circle\",\"1mglay\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"10\"}],[\"$\",\"circle\",\"1vlfrh\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"6\"}],[\"$\",\"circle\",\"1c9p78\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"2\"}],\"$undefined\"]}],[\"$\",\"h1\",null,{\"className\":\"text-6xl font-bold text-white\",\"children\":\"SWOT Analysis\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex-1 min-h-0 grid grid-cols-2 grid-rows-2 gap-6 p-8\",\"children\":[[\"$\",\"div\",null,{\"className\":\"bg-slate-800/90 border-t-4 border-green-400 rounded-lg p-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-4 mb-6\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":36,\"height\":36,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-green-400\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"h3\",null,{\"className\":\"text-4xl font-bold text-green-400\",\"children\":\"Strengths\"}]]}],[\"$\",\"div\",null,{\"className\":\"space-y-3\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-green-400 mt-1\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"First and only FDA-approved PD-L1 inhibitor for advanced cSCC\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-green-400 mt-1\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Differentiated ADCC mechanism beyond checkpoint blockade\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-green-400 mt-1\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Strong clinical data: 47-48% ORR with durable responses\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-green-400 mt-1\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Sun Pharma's global commercialization infrastructure\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-green-400 mt-1\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Favorable safety profile for immunocompromised patients\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-green-400 mt-1\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"$$1B+ addressable U.S. market opportunity\"}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"bg-slate-800/90 border-t-4 border-orange-400 rounded-lg p-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-4 mb-6\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":36,\"height\":36,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-alert text-orange-400\",\"children\":[[\"$\",\"circle\",\"1mglay\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"10\"}],[\"$\",\"line\",\"1pkeuh\",{\"x1\":\"12\",\"x2\":\"12\",\"y1\":\"8\",\"y2\":\"12\"}],[\"$\",\"line\",\"4dfq90\",{\"x1\":\"12\",\"x2\":\"12.01\",\"y1\":\"16\",\"y2\":\"16\"}],\"$undefined\"]}],[\"$\",\"h3\",null,{\"className\":\"text-4xl font-bold text-orange-400\",\"children\":\"Weaknesses\"}]]}],[\"$\",\"div\",null,{\"className\":\"space-y-3\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-alert text-orange-400 mt-1\",\"children\":[[\"$\",\"circle\",\"1mglay\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"10\"}],[\"$\",\"line\",\"1pkeuh\",{\"x1\":\"12\",\"x2\":\"12\",\"y1\":\"8\",\"y2\":\"12\"}],[\"$\",\"line\",\"4dfq90\",{\"x1\":\"12\",\"x2\":\"12.01\",\"y1\":\"16\",\"y2\":\"16\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Late market entry vs. established PD-1 competitors (Keytruda, Libtayo)\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-alert text-orange-400 mt-1\",\"children\":[[\"$\",\"circle\",\"1mglay\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"10\"}],[\"$\",\"line\",\"1pkeuh\",{\"x1\":\"12\",\"x2\":\"12\",\"y1\":\"8\",\"y2\":\"12\"}],[\"$\",\"line\",\"4dfq90\",{\"x1\":\"12\",\"x2\":\"12.01\",\"y1\":\"16\",\"y2\":\"16\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Limited head-to-head clinical trial data\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-alert text-orange-400 mt-1\",\"children\":[[\"$\",\"circle\",\"1mglay\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"10\"}],[\"$\",\"line\",\"1pkeuh\",{\"x1\":\"12\",\"x2\":\"12\",\"y1\":\"8\",\"y2\":\"12\"}],[\"$\",\"line\",\"4dfq90\",{\"x1\":\"12\",\"x2\":\"12.01\",\"y1\":\"16\",\"y2\":\"16\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Historical manufacturing delays (complete response letter)\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-alert text-orange-400 mt-1\",\"children\":[[\"$\",\"circle\",\"1mglay\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"10\"}],[\"$\",\"line\",\"1pkeuh\",{\"x1\":\"12\",\"x2\":\"12\",\"y1\":\"8\",\"y2\":\"12\"}],[\"$\",\"line\",\"4dfq90\",{\"x1\":\"12\",\"x2\":\"12.01\",\"y1\":\"16\",\"y2\":\"16\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Pricing parity strategy limits premium positioning\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-alert text-orange-400 mt-1\",\"children\":[[\"$\",\"circle\",\"1mglay\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"10\"}],[\"$\",\"line\",\"1pkeuh\",{\"x1\":\"12\",\"x2\":\"12\",\"y1\":\"8\",\"y2\":\"12\"}],[\"$\",\"line\",\"4dfq90\",{\"x1\":\"12\",\"x2\":\"12.01\",\"y1\":\"16\",\"y2\":\"16\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Pre-acquisition company had minimal revenue history\"}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"bg-slate-800/90 border-t-4 border-blue-400 rounded-lg p-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-4 mb-6\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":36,\"height\":36,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-trending-up text-blue-400\",\"children\":[[\"$\",\"polyline\",\"126l90\",{\"points\":\"22 7 13.5 15.5 8.5 10.5 2 17\"}],[\"$\",\"polyline\",\"kwv8wd\",{\"points\":\"16 7 22 7 22 13\"}],\"$undefined\"]}],[\"$\",\"h3\",null,{\"className\":\"text-4xl font-bold text-blue-400\",\"children\":\"Opportunities\"}]]}],[\"$\",\"div\",null,{\"className\":\"space-y-3\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-trending-up text-blue-400 mt-1\",\"children\":[[\"$\",\"polyline\",\"126l90\",{\"points\":\"22 7 13.5 15.5 8.5 10.5 2 17\"}],[\"$\",\"polyline\",\"kwv8wd\",{\"points\":\"16 7 22 7 22 13\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Indication expansion: Earlier-stage cSCC, other skin cancers (3-5x population)\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-trending-up text-blue-400 mt-1\",\"children\":[[\"$\",\"polyline\",\"126l90\",{\"points\":\"22 7 13.5 15.5 8.5 10.5 2 17\"}],[\"$\",\"polyline\",\"kwv8wd\",{\"points\":\"16 7 22 7 22 13\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"European market entry: EMA/UK approvals ($250-400M potential)\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-trending-up text-blue-400 mt-1\",\"children\":[[\"$\",\"polyline\",\"126l90\",{\"points\":\"22 7 13.5 15.5 8.5 10.5 2 17\"}],[\"$\",\"polyline\",\"kwv8wd\",{\"points\":\"16 7 22 7 22 13\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Asia-Pacific expansion via Sun Pharma network\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-trending-up text-blue-400 mt-1\",\"children\":[[\"$\",\"polyline\",\"126l90\",{\"points\":\"22 7 13.5 15.5 8.5 10.5 2 17\"}],[\"$\",\"polyline\",\"kwv8wd\",{\"points\":\"16 7 22 7 22 13\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Combination therapy protocols with radiation/other agents\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-trending-up text-blue-400 mt-1\",\"children\":[[\"$\",\"polyline\",\"126l90\",{\"points\":\"22 7 13.5 15.5 8.5 10.5 2 17\"}],[\"$\",\"polyline\",\"kwv8wd\",{\"points\":\"16 7 22 7 22 13\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Biomarker-driven patient selection improving outcomes\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-trending-up text-blue-400 mt-1\",\"children\":[[\"$\",\"polyline\",\"126l90\",{\"points\":\"22 7 13.5 15.5 8.5 10.5 2 17\"}],[\"$\",\"polyline\",\"kwv8wd\",{\"points\":\"16 7 22 7 22 13\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Real-world evidence generation for competitive advantage\"}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"bg-slate-800/90 border-t-4 border-red-400 rounded-lg p-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-4 mb-6\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":36,\"height\":36,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-triangle-alert text-red-400\",\"children\":[[\"$\",\"path\",\"wmoenq\",{\"d\":\"m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3\"}],[\"$\",\"path\",\"juzpu7\",{\"d\":\"M12 9v4\"}],[\"$\",\"path\",\"p32p05\",{\"d\":\"M12 17h.01\"}],\"$undefined\"]}],[\"$\",\"h3\",null,{\"className\":\"text-4xl font-bold text-red-400\",\"children\":\"Threats\"}]]}],[\"$\",\"div\",null,{\"className\":\"space-y-3\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-triangle-alert text-red-400 mt-1\",\"children\":[[\"$\",\"path\",\"wmoenq\",{\"d\":\"m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3\"}],[\"$\",\"path\",\"juzpu7\",{\"d\":\"M12 9v4\"}],[\"$\",\"path\",\"p32p05\",{\"d\":\"M12 17h.01\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Intense competition from Keytruda/Libtayo with established market share\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-triangle-alert text-red-400 mt-1\",\"children\":[[\"$\",\"path\",\"wmoenq\",{\"d\":\"m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3\"}],[\"$\",\"path\",\"juzpu7\",{\"d\":\"M12 9v4\"}],[\"$\",\"path\",\"p32p05\",{\"d\":\"M12 17h.01\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Potential biosimilar competition post-patent expiration (2036+)\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-triangle-alert text-red-400 mt-1\",\"children\":[[\"$\",\"path\",\"wmoenq\",{\"d\":\"m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3\"}],[\"$\",\"path\",\"juzpu7\",{\"d\":\"M12 9v4\"}],[\"$\",\"path\",\"p32p05\",{\"d\":\"M12 17h.01\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Reimbursement challenges and payer utilization management\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-triangle-alert text-red-400 mt-1\",\"children\":[[\"$\",\"path\",\"wmoenq\",{\"d\":\"m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3\"}],[\"$\",\"path\",\"juzpu7\",{\"d\":\"M12 9v4\"}],[\"$\",\"path\",\"p32p05\",{\"d\":\"M12 17h.01\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Emerging next-generation checkpoint inhibitors\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-triangle-alert text-red-400 mt-1\",\"children\":[[\"$\",\"path\",\"wmoenq\",{\"d\":\"m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3\"}],[\"$\",\"path\",\"juzpu7\",{\"d\":\"M12 9v4\"}],[\"$\",\"path\",\"p32p05\",{\"d\":\"M12 17h.01\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Healthcare reform and drug pricing legislation risks\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":16,\"height\":16,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-triangle-alert text-red-400 mt-1\",\"children\":[[\"$\",\"path\",\"wmoenq\",{\"d\":\"m21.73 18-8-14a2 2 0 0 0-3.48 0l-8 14A2 2 0 0 0 4 21h16a2 2 0 0 0 1.73-3\"}],[\"$\",\"path\",\"juzpu7\",{\"d\":\"M12 9v4\"}],[\"$\",\"path\",\"p32p05\",{\"d\":\"M12 17h.01\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Manufacturing and supply chain vulnerabilities\"}]]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex-none p-4 text-right\",\"children\":[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-400\",\"children\":\"7\"}]}]]}]}],null],null],null]},[null,[\"$\",\"$L5\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"pages\",\"children\",\"7\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L6\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\"}]],null]},[null,[\"$\",\"$L5\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"pages\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L6\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\"}]],null]},[[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/8d323862949ffad9.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\"}]],[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"dark\",\"children\":[\"$\",\"body\",null,{\"className\":\"__className_f367f3 h-1080px w-1920px\",\"children\":[[\"$\",\"$7\",null,{\"fallback\":null,\"children\":[[\"$\",\"$L8\",null,{}],[\"$\",\"$L9\",null,{}]]}],[\"$\",\"$L5\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L6\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"title\",null,{\"children\":\"404: This page could not be found.\"}],[\"$\",\"div\",null,{\"style\":{\"fontFamily\":\"system-ui,\\\"Segoe UI\\\",Roboto,Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\"\",\"height\":\"100vh\",\"textAlign\":\"center\",\"display\":\"flex\",\"flexDirection\":\"column\",\"alignItems\":\"center\",\"justifyContent\":\"center\"},\"children\":[\"$\",\"div\",null,{\"children\":[[\"$\",\"style\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}\"}}],[\"$\",\"h1\",null,{\"className\":\"next-error-h1\",\"style\":{\"display\":\"inline-block\",\"margin\":\"0 20px 0 0\",\"padding\":\"0 23px 0 0\",\"fontSize\":24,\"fontWeight\":500,\"verticalAlign\":\"top\",\"lineHeight\":\"49px\"},\"children\":\"404\"}],[\"$\",\"div\",null,{\"style\":{\"display\":\"inline-block\"},\"children\":[\"$\",\"h2\",null,{\"style\":{\"fontSize\":14,\"fontWeight\":400,\"lineHeight\":\"49px\",\"margin\":0},\"children\":\"This page could not be found.\"}]}]]}]}]],\"notFoundStyles\":[]}]]}]}]],null],null],\"couldBeIntercepted\":false,\"initialHead\":[null,\"$La\"],\"globalErrorComponent\":\"$b\",\"missingSlots\":\"$Wc\"}]\n"])</script><script>self.__next_f.push([1,"a:[[\"$\",\"meta\",\"0\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}],[\"$\",\"meta\",\"1\",{\"charSet\":\"utf-8\"}],[\"$\",\"title\",\"2\",{\"children\":\"Unloxcyt Market Survey - Interactive Presentation\"}],[\"$\",\"meta\",\"3\",{\"name\":\"description\",\"content\":\"Comprehensive market analysis of Cosibelimab-ipdl for advanced cSCC\"}],[\"$\",\"meta\",\"4\",{\"name\":\"next-size-adjust\"}]]\n4:null\n"])</script></body></html>